Email ID
Password
Scrip   
Amgen TAPs second ImmunoGen licence
23 November 2009
Sukaina Virji

Amgen has exclusively licensed ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such licence to be taken by Amgen – it obtained the exclusive right to use ImmunoGen’s TAP technology for...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36